EMERGENT BIOSOLUTIONS INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
EMERGENT BIOSOLUTIONS INC. (EBS) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for fiscal 2018 was $0.00.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $10.60M, a 6.04% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $11.28M, a 88.42% increase from fiscal 2014.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-22 | |||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 derived: sum of 2 quarters · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | -$225.00K derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | -$225.00K derived: sum of 3 quarters · filed 2019-02-22 | $158.00K derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | -$225.00K derived: sum of 2 quarters · filed 2019-02-22 | $158.00K derived: sum of 3 quarters · filed 2019-02-22 | $4.81M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | -$225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $158.00K derived: sum of 2 quarters · filed 2019-02-22 | $4.81M derived: sum of 3 quarters · filed 2019-02-22 | $10.60M 10-K · filed 2019-02-22 | $10.62M 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $5.04M derived: sum of 2 quarters · filed 2017-11-03 | $10.82M 10-Q · filed 2017-11-03 | $14.10M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $10.44M 10-Q · filed 2017-08-04 | $13.72M derived: sum of 3 quarters · filed 2018-02-23 | $14.48M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $5.79M 10-Q · filed 2017-05-05 | $9.06M derived: sum of 2 quarters · filed 2018-02-23 | $9.83M derived: sum of 3 quarters · filed 2018-02-23 | $11.65M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $4.04M derived: sum of 2 quarters · filed 2018-02-23 | $5.87M derived: sum of 3 quarters · filed 2018-02-23 | $11.28M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $761.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.59M derived: sum of 2 quarters · filed 2016-11-09 | $8.00M 10-Q · filed 2016-11-09 | $8.42M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $7.24M 10-Q · filed 2016-08-05 | $7.66M derived: sum of 3 quarters · filed 2017-02-28 | $8.05M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $5.41M 10-Q · filed 2016-05-06 | $5.83M derived: sum of 2 quarters · filed 2017-02-28 | $6.22M derived: sum of 3 quarters · filed 2017-02-28 | $6.83M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $808.00K derived: sum of 2 quarters · filed 2017-02-28 | $1.42M derived: sum of 3 quarters · filed 2017-02-28 | $5.99M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $387.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $996.00K derived: sum of 2 quarters · filed 2015-11-06 | $5.57M 10-Q · filed 2015-11-06 | $6.72M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $609.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $5.18M 10-Q · filed 2015-08-06 | $6.33M derived: sum of 3 quarters · filed 2016-02-29 | $6.52M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $4.57M 10-Q · filed 2015-05-08 | $5.72M derived: sum of 2 quarters · filed 2016-02-29 | $5.91M derived: sum of 3 quarters · filed 2016-02-29 | $6.06M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.34M derived: sum of 2 quarters · filed 2016-02-29 | $1.49M derived: sum of 3 quarters · filed 2016-02-29 | $3.10M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $341.00K derived: sum of 2 quarters · filed 2014-11-10 | $1.95M 10-Q · filed 2014-11-10 | $2.06M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $149.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.76M 10-Q · filed 2014-08-08 | $1.86M derived: sum of 3 quarters · filed 2015-03-09 | $2.04M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | $1.61M 10-Q · filed 2014-05-12 | $1.71M derived: sum of 2 quarters · filed 2015-03-09 | $1.89M derived: sum of 3 quarters · filed 2015-03-09 | $2.08M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $281.00K derived: sum of 2 quarters · filed 2015-03-09 | $470.00K derived: sum of 3 quarters · filed 2015-03-09 | $1.59M 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $364.00K derived: sum of 2 quarters · filed 2013-11-08 | $1.48M 10-Q · filed 2013-11-08 | -$1.49M 10-Q · filed 2012-11-01 | $4.59M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2012-06-30 | $189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $1.31M 10-Q · filed 2013-08-06 | -$1.25M 10-Q · filed 2012-08-03 | $4.41M derived: sum of 3 quarters · filed 2014-03-10 | $4.13M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2012-03-31 | $1.12M 10-Q · filed 2013-05-03 | -$862.00K 10-Q · filed 2012-05-04 | $4.22M derived: sum of 2 quarters · filed 2014-03-10 | $3.94M derived: sum of 3 quarters · filed 2014-03-10 | $5.69M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2011-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $2.82M derived: sum of 2 quarters · filed 2014-03-10 | $4.57M derived: sum of 3 quarters · filed 2014-03-10 | $4.61M 10-K · filed 2014-03-10 | $2.20M 10-K · filed 2012-03-09 | |||
| 2011-09-30 | -$284.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $1.46M derived: sum of 2 quarters · filed 2012-11-01 | $1.50M 10-Q · filed 2012-11-01 | $3.03M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $1.79M 10-Q · filed 2012-08-03 | $3.32M derived: sum of 3 quarters · filed 2013-03-08 | $3.69M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-03-31 | $39.00K 10-Q · filed 2012-05-04 | $1.57M derived: sum of 2 quarters · filed 2013-03-08 | $1.94M derived: sum of 3 quarters · filed 2013-03-08 | |||||
| 2010-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $1.90M derived: sum of 2 quarters · filed 2013-03-08 | $2.61M 10-K · filed 2013-03-08 | $1.70M 10-K · filed 2012-03-09 | ||||
| 2010-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $1.08M 10-Q · filed 2011-11-04 | ||||||
| 2010-06-30 | $709.00K 10-Q · filed 2011-08-05 | |||||||
| 2009-12-31 | $1.85M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |